Genmab A/S (NASDAQ:GMAB) Short Interest Update

Genmab A/S (NASDAQ:GMAB) saw a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 2,340,000 shares, a growth of 23.2% from the October 15th total of 1,900,000 shares. Approximately 0.4% of the shares of the company are sold short. Based on an average trading volume of 874,600 shares, the days-to-cover ratio is presently 2.7 days.

Genmab A/S Price Performance

Shares of Genmab A/S stock traded down $0.59 on Friday, hitting $20.59. 1,310,575 shares of the company’s stock traded hands, compared to its average volume of 1,554,565. Genmab A/S has a one year low of $20.50 and a one year high of $32.89. The company has a fifty day moving average of $23.81 and a two-hundred day moving average of $26.18. The company has a market capitalization of $13.63 billion, a price-to-earnings ratio of 19.99, a price-to-earnings-growth ratio of 0.64 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The company had revenue of $816.10 million for the quarter, compared to analyst estimates of $838.20 million. During the same quarter in the prior year, the company posted $0.47 EPS. Equities research analysts anticipate that Genmab A/S will post 1.28 earnings per share for the current year.

Institutional Trading of Genmab A/S

A number of hedge funds and other institutional investors have recently bought and sold shares of GMAB. MML Investors Services LLC increased its holdings in Genmab A/S by 5.4% during the 3rd quarter. MML Investors Services LLC now owns 73,261 shares of the company’s stock worth $1,786,000 after purchasing an additional 3,785 shares in the last quarter. XTX Topco Ltd grew its holdings in Genmab A/S by 116.4% during the third quarter. XTX Topco Ltd now owns 25,429 shares of the company’s stock worth $620,000 after buying an additional 13,678 shares in the last quarter. Two Sigma Advisers LP raised its position in Genmab A/S by 84.1% in the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock valued at $14,996,000 after buying an additional 280,900 shares during the last quarter. Quantinno Capital Management LP raised its position in Genmab A/S by 56.8% in the 3rd quarter. Quantinno Capital Management LP now owns 24,207 shares of the company’s stock valued at $590,000 after buying an additional 8,766 shares during the last quarter. Finally, HighTower Advisors LLC bought a new position in Genmab A/S during the 3rd quarter valued at $273,000. Institutional investors own 7.07% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on GMAB shares. Truist Financial reduced their target price on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a report on Monday, September 9th. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a report on Wednesday, October 16th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Genmab A/S in a report on Tuesday, August 20th. BMO Capital Markets reiterated an “outperform” rating and set a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Finally, Redburn Atlantic initiated coverage on Genmab A/S in a research report on Tuesday, October 8th. They issued a “buy” rating for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.